Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Daiichi Sankyo's Herceptin Biosimilar Now in Line for September Approval as It Clears MHLW Panel
August 6, 2018
- MHLW Vaccine Panel to Continue Discussion on Pneumococcus in Elderly, Inactivated Polio Vaccine
August 3, 2018
- MHLW Panel Rebuffs Nonprescription Switches of 3 PPIs
August 3, 2018
- MHLW Orders Label Revisions for Otezla, Ceftriaxone
August 3, 2018
- Fusion of Registry Network and MID-NET Will Change Clinical Trial Landscape in Japan: MHLW Official
July 31, 2018
- Inappropriate Drug Promotion at Clinics Involves Encouragement of Off-Label Use in Most Cases: Study
July 31, 2018
- Boehringer’s DPP-4/SGLT2 Combo Clears MHLW Panel
July 30, 2018
- Govt Revises Basic Policy of Asia Health Initiative, with New Focus on Promoting Access to Drugs in Asia
July 27, 2018
- MHLW Panel Wraps Up 1st Round of Debates on PMD Law Amendment, Elaborate Discussions Slated to Start in September
July 26, 2018
- MHLW Shuffles Senior Bureaucrats, Health Insurance Chief Suzuki Tapped for Top Post
July 25, 2018
- AMED Launches Study on Evaluating the Quality and Safety of Nucleic Acid Medicines to Promote Their Development
July 25, 2018
- Discussions Needed for “Biosame” Products: MHLW Official
July 24, 2018
- Lilly’s Breast Cancer Med Abemaciclib Up for MHLW Panel Review on Aug. 3
July 23, 2018
- Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate
July 19, 2018
- Scope of Japan-EU GMP Mutual Recognition Agreement for Pharmaceuticals Expanded: MHLW
July 19, 2018
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27
July 17, 2018
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices
July 17, 2018
- New Medical Infrastructure Law to Pave Way for Database on 50 Million People: Govt Official
July 13, 2018
- MHLW Orders Removal of Pregnancy Contraindications for 3 Immunosuppressants
July 12, 2018
- MHLW Selects 9 Priority Prefectures for Generic Promotion Project, but Leaves Tokyo Out
July 12, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…